Hans Hull Pliant Therapeutics, Inc. (PLRX) insider trading activity

Hans Hull is Chief Business Officer of PLIANT THERAPEUTICS, INC.. Currently has a direct ownership of 251,708 shares of PLRX, which is worth approximately $2.7 Million. The most recent transaction as insider was on Jan 23, 2025, when has been sold 40,150 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 252K

10.64% 3M change

16.23% 12M change

Total Value Held $2.7 Million

Hans Hull Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 23 2025	BUY Grant, award, or other acquisition	-	40,150 Added 13.76%	251,708 Common Stock
Jan 17 2025	SELL Open market or private sale	$178,483 $11.2 p/Share	15,936 Reduced 7.01%	211,558 Common Stock
Jul 10 2024	SELL Open market or private sale	$114,444 $11.56 p/Share	9,900 Reduced 4.17%	227,494 Common Stock
Jul 09 2024	BUY Grant, award, or other acquisition	-	19,337 Added 7.53%	237,394 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	31,500 Added 12.7%	216,569 Common Stock
Jan 17 2024	SELL Open market or private sale	$168,612 $17.23 p/Share	9,786 Reduced 5.02%	185,069 Common Stock
Aug 04 2023	SELL Open market or private sale	$401,200 $20.01 p/Share	20,050 Reduced 9.33%	194,855 Common Stock
Aug 04 2023	BUY Exercise of conversion of derivative security	$18,285 $2.08 p/Share	8,791 Added 3.93%	214,905 Common Stock
Aug 03 2023	SELL Open market or private sale	$261,380 $20.0 p/Share	13,069 Reduced 5.96%	206,114 Common Stock
Aug 03 2023	BUY Open market or private sale	$36,000 $20.0 p/Share	1,800 Added 0.87%	206,114 Common Stock
Aug 03 2023	BUY Exercise of conversion of derivative security	$3,744 $2.08 p/Share	1,800 Added 0.86%	207,914 Common Stock
Jul 17 2023	SELL Open market or private sale	$323,045 $18.01 p/Share	17,937 Reduced 7.56%	219,183 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	-	35,156 Added 12.91%	237,120 Common Stock
Mar 30 2023	SELL Open market or private sale	$239,634 $26.52 p/Share	9,036 Reduced 4.28%	201,964 Common Stock
Mar 29 2023	BUY Grant, award, or other acquisition	-	17,578 Added 7.69%	211,000 Common Stock
Jan 25 2023	BUY Grant, award, or other acquisition	-	54,000 Added 21.93%	192,191 Common Stock
Dec 20 2022	SELL Open market or private sale	$167,086 $19.1 p/Share	8,748 Reduced 5.95%	138,191 Common Stock
Dec 19 2022	BUY Grant, award, or other acquisition	-	17,578 Added 10.68%	146,939 Common Stock
May 26 2021	BUY Exercise of conversion of derivative security	$9,360 $2.08 p/Share	4,500 Added 3.47%	125,246 Common Stock
Dec 30 2020	BUY Exercise of conversion of derivative security	$7,280 $2.08 p/Share	3,500 Added 2.82%	120,746 Common Stock

Hans Hull

Chief Business Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PLRX shares.

Notify only if

Value

Insider Trading

Get notified when an Pliant Therapeutics, Inc. insider buys or sells PLRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to PLIANT THERAPEUTICS, INC.

Track Activities on PLRX

Account